These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34511333)

  • 21. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A long-term, open-label study of valbenazine for tardive dyskinesia.
    Lindenmayer JP; Verghese C; Marder SR; Burke J; Jimenez R; Siegert S; Liang GS; O'Brien CF
    CNS Spectr; 2021 Aug; 26(4):345-353. PubMed ID: 32419679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
    Dorfman BJ; Jimenez-Shahed J
    Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440
    [No Abstract]   [Full Text] [Related]  

  • 24. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM
    Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
    Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
    Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
    ; Frank S; Testa CM; Stamler D; Kayson E; Davis C; Edmondson MC; Kinel S; Leavitt B; Oakes D; O'Neill C; Vaughan C; Goldstein J; Herzog M; Snively V; Whaley J; Wong C; Suter G; Jankovic J; Jimenez-Shahed J; Hunter C; Claassen DO; Roman OC; Sung V; Smith J; Janicki S; Clouse R; Saint-Hilaire M; Hohler A; Turpin D; James RC; Rodriguez R; Rizer K; Anderson KE; Heller H; Carlson A; Criswell S; Racette BA; Revilla FJ; Nucifora F; Margolis RL; Ong M; Mendis T; Mendis N; Singer C; Quesada M; Paulsen JS; Brashers-Krug T; Miller A; Kerr J; Dubinsky RM; Gray C; Factor SA; Sperin E; Molho E; Eglow M; Evans S; Kumar R; Reeves C; Samii A; Chouinard S; Beland M; Scott BL; Hickey PT; Esmail S; Fung WL; Gibbons C; Qi L; Colcher A; Hackmyer C; McGarry A; Klos K; Gudesblatt M; Fafard L; Graffitti L; Schneider DP; Dhall R; Wojcieszek JM; LaFaver K; Duker A; Neefus E; Wilson-Perez H; Shprecher D; Wall P; Blindauer KA; Wheeler L; Boyd JT; Houston E; Farbman ES; Agarwal P; Eberly SW; Watts A; Tariot PN; Feigin A; Evans S; Beck C; Orme C; Edicola J; Christopher E
    JAMA; 2016 Jul; 316(1):40-50. PubMed ID: 27380342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA; Proctor GJ; Stahl SM
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
    Factor SA; Remington G; Comella CL; Correll CU; Burke J; Jimenez R; Liang GS; O'Brien CF
    J Clin Psychiatry; 2017; 78(9):1344-1350. PubMed ID: 29141124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
    Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM;
    JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
    Jankovic J; Coffey B; Claassen DO; Jimenez-Shahed J; Gertz BJ; Garofalo EA; Stamler DA; Wieman M; Savola JM; Gordon MF; Alexander J; Barkay H; Harary E
    JAMA Netw Open; 2021 Oct; 4(10):e2128204. PubMed ID: 34609495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
    Coffey B; Jankovic J; Claassen DO; Jimenez-Shahed J; Gertz BJ; Garofalo EA; Stamler DA; Wieman M; Savola JM; Gordon MF; Alexander JK; Barkay H; Harary E
    JAMA Netw Open; 2021 Oct; 4(10):e2129397. PubMed ID: 34661664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence.
    McEvoy JP
    J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT).
    Horiguchi J; Watanabe K; Kondo K; Iwatake A; Sakamoto H; Susuta Y; Masui H; Watanabe Y
    Psychiatry Clin Neurosci; 2022 Nov; 76(11):560-569. PubMed ID: 36114799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
    Citrome LL
    J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM; Nicewonder JA
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care.
    McEvoy JP
    J Clin Psychiatry; 2020 Nov; 81(6):. PubMed ID: 33147658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect.
    Schneider F; Stamler D; Bradbury M; Loupe PS; Hellriegel E; Cox DS; Savola JM; Gordon MF; Rabinovich-Guilatt L
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):647-659. PubMed ID: 33038289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.